Literature DB >> 17499486

Vesicle size and stability of biomimetic liposomes from 3'-sulfo-Lewis a (SuLea) containing glycolipids.

Junmin Zhu1, Jie Xue, Zhongwu Guo, Roger E Marchant.   

Abstract

We report on the use of a natural Lewis type saccharide ligand, 3'-sulfo-Lewis a (SuLe(a)) for glycocalyx-mimetic surface modification of liposomes. Two SuLe(a)-containing glycolipids, monovalent SuLe(a)-lipid and trivalent SuLe(a) (TSuLe(a))-lipid, were synthesized, and used with 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and cholesterol to prepare unilaminar vesicles (ULVs) by a freeze-thaw and extrusion method. The effects of the glycolipid concentrations and the pore sizes of extrusion membranes on vesicle size and stability were investigated by photon correlation spectroscopy (PCS). Glycoliposomes, with 5% SuLe(a)- or TSuLe(a)-lipids obtained by 50 nm extrusion, had 25-30% more vesicles less than 100 nm in diameter compared with the 100 nm extrusion. TSuLe(a)-liposomes always produced larger vesicle size than SuLe(a)-liposomes, which we attribute to the larger TSuLe(a) headgroup. Both SuLe(a)- and TSuLe(a)-liposomes increased their vesicle size with increasing glycolipid concentration from 5% to 15%, and demonstrated good stability at room temperature for over 1 month. Further increasing the glycolipid concentration to 20% resulted in large vesicle aggregation after 5 days for TSuLe(a)-liposomes, while the SuLe(a)-liposomes remained stable for 10 days. SuLe(a)- and TSuLe(a)-liposomes with 15% glycolipids demonstrated better stability due to the electrostatic effect from the negatively charged SuLe(a) and TSuLe(a) headgroups. The results indicate that the biomimetic liposomes with SuLe(a)- and TSuLe(a)-lipids with 5 to 15% incorporation are sufficiently stable for the potential applications in targeted drug delivery.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17499486      PMCID: PMC2041829          DOI: 10.1016/j.colsurfb.2007.03.016

Source DB:  PubMed          Journal:  Colloids Surf B Biointerfaces        ISSN: 0927-7765            Impact factor:   5.268


  37 in total

Review 1.  Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors.

Authors:  D C Drummond; O Meyer; K Hong; D B Kirpotin; D Papahadjopoulos
Journal:  Pharmacol Rev       Date:  1999-12       Impact factor: 25.468

2.  The pressure-dependence of the size of extruded vesicles.

Authors:  Philipus J Patty; Barbara J Frisken
Journal:  Biophys J       Date:  2003-08       Impact factor: 4.033

3.  Size and structure of spontaneously forming liposomes in lipid/PEG-lipid mixtures.

Authors:  Montse Rovira-Bru; David H Thompson; Igal Szleifer
Journal:  Biophys J       Date:  2002-11       Impact factor: 4.033

4.  Surface modification of liposomes by saccharides: vesicle size and stability of lactosyl liposomes studied by photon correlation spectroscopy.

Authors:  Junmin Zhu; Feng Yan; Zhongwu Guo; Roger E Marchant
Journal:  J Colloid Interface Sci       Date:  2005-09-15       Impact factor: 8.128

5.  Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes.

Authors:  A L Klibanov; K Maruyama; V P Torchilin; L Huang
Journal:  FEBS Lett       Date:  1990-07-30       Impact factor: 4.124

Review 6.  Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol).

Authors:  C Allen; N Dos Santos; R Gallagher; G N C Chiu; Y Shu; W M Li; S A Johnstone; A S Janoff; L D Mayer; M S Webb; M B Bally
Journal:  Biosci Rep       Date:  2002-04       Impact factor: 3.840

Review 7.  The sweet and sour of cancer: glycans as novel therapeutic targets.

Authors:  Mark M Fuster; Jeffrey D Esko
Journal:  Nat Rev Cancer       Date:  2005-07       Impact factor: 60.716

Review 8.  Liposomal drug formulations. Rationale for development and what we can expect for the future.

Authors:  T M Allen
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

9.  Molecular mechanism of the lipid vesicle longevity in vivo.

Authors:  G Blume; G Cevc
Journal:  Biochim Biophys Acta       Date:  1993-03-14

10.  Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors.

Authors:  A Gabizon; D Papahadjopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

View more
  3 in total

1.  The use of phospholipid nanoparticles for increasing Semax resistance in various proteolytic biological media.

Authors:  K V Shevchenko; A P Khrapko; V I Schwets; N F Myasoyedov
Journal:  Dokl Biol Sci       Date:  2009 Nov-Dec

2.  Surface-engineered nanoliposomes by chelating ligands for modulating the neurotoxicity associated with β-amyloid aggregates of Alzheimer's disease.

Authors:  Maluta S Mufamadi; Yahya E Choonara; Pradeep Kumar; Girish Modi; Dinesh Naidoo; Valence M K Ndesendo; Lisa C du Toit; Sunny E Iyuke; Viness Pillay
Journal:  Pharm Res       Date:  2012-05-15       Impact factor: 4.200

Review 3.  Challenges in development of nanoparticle-based therapeutics.

Authors:  Neil Desai
Journal:  AAPS J       Date:  2012-03-10       Impact factor: 4.009

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.